Atle Fund Management AB
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Atle Fund Management AB reported 38 stock positions worth $164.0 million. Its top holding was Eli Lilly (LLY) at 15.0% of the portfolio, followed by Unitedhealth (UNH, 9.8%) and Merck (MRK, 8.5%). Compared with Q1 2024, it opened 3 new positions, sold out of 9, added to 23 and reduced 11. The biggest buy was Eli Lilly (LLY, shares +31%) and the biggest sale Harmony Biosciences (HRMY, shares −79%).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $164.0M (Q2 2024)
- SEC Filing
- 0001381843-24-000006 ↗ filed Aug 14, 2024
Holdings Value
Holdings 38 stocks · $164.0M
| LLY Eli Lilly & Co. | 14.98% | 27,144 | $24.6M | Add +30.6% |
| UNH Unitedhealth Group Inc. | 9.84% | 31,680 | $16.1M | Add +37.5% |
| MRK Merck & Co. Inc. | 8.51% | 112,734 | $14.0M | Reduce -15.7% |
| TMO Thermo Fisher Scientific Inc. | 6.56% | 19,458 | $10.8M | Add +28.1% |
| AMGN Amgen Inc. | 5.26% | 27,589 | $8.6M | Add +46.0% |
| BSX Boston Scientific Corp. | 5.00% | 106,557 | $8.2M | Add +37.7% |
| REGN Regeneron Pharmaceuticals | 4.42% | 6,893 | $7.2M | Add +27.8% |
| VRTX Vertex Pharmaceuticals Inc. | 4.31% | 15,095 | $7.1M | Add +33.6% |
| COR Cencora Inc. | 4.17% | 30,320 | $6.8M | Add +48.4% |
| SYK Stryker Corp. | 4.15% | 19,983 | $6.8M | Add +31.9% |
| ABBV Abbvie Inc. | 3.73% | 35,618 | $6.1M | Add +21.4% |
| DXCM Dexcom Inc. | 2.38% | 34,483 | $3.9M | Add +31.2% |
| EW Edwards Lifesciences Corp. | 2.06% | 36,505 | $3.4M | Add +47.4% |
| NBIX Neurocrine Biosciences Inc. | 1.98% | 23,630 | $3.3M | Reduce -45.6% |
| IQV Iqvia Holdings Inc. | 1.80% | 13,984 | $3.0M | Add +39.0% |
| MOH Molina Healthcare Inc. | 1.72% | 9,500 | $2.8M | Reduce -20.8% |
| CAH Cardinal Health Inc. | 1.65% | 27,500 | $2.7M | No change |
| UFPT Ufp Technologies Inc. | 1.58% | 9,800 | $2.6M | New |
| MIRM Mirum Pharmaceuticals Inc. | 1.57% | 75,200 | $2.6M | Reduce -38.9% |
| ITCI Intra-Cellular Therapies Inc. | 1.50% | 35,841 | $2.5M | Reduce -5.8% |
| IONS Ionis Pharmaceuticals Inc. | 1.18% | 40,691 | $1.9M | Reduce -36.2% |
| MRUS Merus NV | 1.11% | 30,837 | $1.8M | Add +26.8% |
| CRBP Corbus Pharmaceuticals Holdi | 1.08% | 39,100 | $1.8M | Add +2.9% |
| ALKS Alkermes PLC | 1.01% | 68,800 | $1.7M | New |
| OPCH Option Care Health Inc. | 0.92% | 54,395 | $1.5M | Reduce -59.1% |
| FOLD Amicus Therapeutics Inc. | 0.90% | 148,207 | $1.5M | Reduce -41.3% |
| NAMS Newamsterdam Pharma Co. NV | 0.89% | 75,794 | $1.5M | Add +238.5% |
| KRYS Krystal Biotech Inc. | 0.85% | 7,624 | $1.4M | Add +15.1% |
| BBIO Bridgebio Pharma Inc. | 0.83% | 53,432 | $1.4M | Add +41.2% |
| ACLX Arcellx Inc. | 0.76% | 22,496 | $1.2M | Add +28.6% |
| HRMY Harmony Biosciences Holdings | 0.64% | 34,900 | $1.1M | Reduce -79.5% |
| IMCR Immunocore Holdings PLC-ADR | 0.49% | 23,778 | $806K | Reduce -41.9% |
| AUTL Autolus Therapeutics PLC | 0.48% | 226,145 | $787K | Add +134.7% |
| MORF Morphic Holding Inc. | 0.42% | 20,199 | $688K | Add +35.1% |
| PHVS Pharvaris NV | 0.39% | 34,328 | $645K | New |
| MGNX Macrogenics Inc. | 0.37% | 143,407 | $609K | Add +190.8% |
| CABA Cabaletta Bio Inc. | 0.29% | 64,321 | $481K | Reduce -17.1% |
| MERSANA THERAPEUTICS INC | 0.23% | 184,900 | $372K | Add +84.9% |
Portfolio Sells Q1 2024 → Q2 2024
| HRMY Harmony Biosciences Holdings | Reduce -79.5% | 0.64% | −2.83 |
| ELV Elevance Health Inc. | Sold out | 0.00% | −2.33 |
| GILD Gilead Sciences Inc. | Sold out | 0.00% | −2.32 |
| MRK Merck & Co. Inc. | Reduce -15.7% | 8.51% | −2.23 |
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −1.80 |
| OPCH Option Care Health Inc. | Reduce -59.1% | 0.92% | −1.79 |
| NBIX Neurocrine Biosciences Inc. | Reduce -45.6% | 1.98% | −1.67 |
| MOH Molina Healthcare Inc. | Reduce -20.8% | 1.72% | −1.28 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -41.9% | 0.49% | −1.13 |
| SWAV Shockwave Medical Inc. | Sold out | 0.00% | −0.94 |
| FOLD Amicus Therapeutics Inc. | Reduce -41.3% | 0.90% | −0.91 |
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −0.68 |
| INSP Inspire Medical Systems Inc. | Sold out | 0.00% | −0.63 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.60 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −0.57 |
| CABA Cabaletta Bio Inc. | Reduce -17.1% | 0.29% | −0.51 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -36.2% | 1.18% | −0.50 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −0.38 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -38.9% | 1.57% | −0.31 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -5.8% | 1.50% | −0.11 |
Portfolio Buys Q1 2024 → Q2 2024
| LLY Eli Lilly & Co. | Add +30.6% | 14.98% | +5.15 |
| UNH Unitedhealth Group Inc. | Add +37.5% | 9.84% | +2.90 |
| AMGN Amgen Inc. | Add +46.0% | 5.26% | +1.99 |
| BSX Boston Scientific Corp. | Add +37.7% | 5.00% | +1.78 |
| UFPT Ufp Technologies Inc. | New | 1.58% | +1.58 |
| VRTX Vertex Pharmaceuticals Inc. | Add +33.6% | 4.31% | +1.44 |
| REGN Regeneron Pharmaceuticals | Add +27.8% | 4.42% | +1.26 |
| TMO Thermo Fisher Scientific Inc. | Add +28.1% | 6.56% | +1.19 |
| COR Cencora Inc. | Add +48.4% | 4.17% | +1.15 |
| ALKS Alkermes PLC | New | 1.01% | +1.01 |
| SYK Stryker Corp. | Add +31.9% | 4.15% | +0.85 |
| EW Edwards Lifesciences Corp. | Add +47.4% | 2.06% | +0.62 |
| NAMS Newamsterdam Pharma Co. NV | Add +238.5% | 0.89% | +0.57 |
| ABBV Abbvie Inc. | Add +21.4% | 3.73% | +0.47 |
| MRUS Merus NV | Add +26.8% | 1.11% | +0.45 |
| PHVS Pharvaris NV | New | 0.39% | +0.39 |
| IQV Iqvia Holdings Inc. | Add +39.0% | 1.80% | +0.26 |
| CRBP Corbus Pharmaceuticals Holdi | Add +2.9% | 1.08% | +0.17 |
| DXCM Dexcom Inc. | Add +31.2% | 2.38% | +0.17 |
| KRYS Krystal Biotech Inc. | Add +15.1% | 0.85% | +0.14 |
| BBIO Bridgebio Pharma Inc. | Add +41.2% | 0.83% | +0.11 |
| AUTL Autolus Therapeutics PLC | Add +134.7% | 0.48% | +0.11 |
| MORF Morphic Holding Inc. | Add +35.1% | 0.42% | +0.10 |
| ACLX Arcellx Inc. | Add +28.6% | 0.76% | +0.02 |
| MERSANA THERAPEUTICS INC | Add +84.9% | 0.23% | −0.05 |
| MGNX Macrogenics Inc. | Add +190.8% | 0.37% | −0.07 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |